
RIBOMIC Announces Presentation Materials of the 40th Annual J.P. Morgan Healthcare Conference

TOKYO, January 11, 2022 - RIBOMIC, Inc., a clinical stage pharmaceutical company specializing in aptamer therapeutics (TYO:4591), today announced that Yoshikazu Nakamura Ph.D., President and CEO, gave a corporate presentation at the 40th J.P. Morgan Healthcare Conference. Presentation materials are available at the following URL.

URL : <https://ssl4.eir-parts.net/doc/4591/announcement6/75009/00.pdf>

See RIBOMIC website for more information.

<https://www.ribomic.com/eng/>

Forward-Looking Statements

This announcement contains forward-looking statements relating to current plans, estimates, strategies, belief and the future performance of Company. These statements are based on Company's current expectations in light of the information and assumptions currently available so that Company does not promise the realization and these expectations may differ materially from those discussed in the forward-looking statements. These factors include, but not limited to, i) changes in general economic conditions and in laws and regulations, relating to pharmaceutical markets, ii) currency exchange rate fluctuations, iii) claims and concerns on the product safety and efficacy, iv) completion and discontinuation of clinical trials, v) infringement of Company's intellectual property rights by third parties.

Information on pharmaceutical products (including products currently in development), which is included in this press release is not intended to constitute an advertisement or medical advice.

"RIBOMIC," "RiboART system" and the RIBOMIC logo are registered trademarks or trademarks of RIBOMIC Inc. in various jurisdictions.

Contacts for inquiries or additional information:

RIBOMIC Inc.

ir.inquiry@ribomic.com